BIOTECH CATALYST AI SCANNER — August WK4

September is going to be loud. Nine of the twenty names below carry a Q3 window that has not yet closed, and almost all of them land in the same four-week stretch: uniQure's four-year Huntington's data and BLA, Immix's registrational CAR-T topline, two Invivyd Phase 3s reading out together, Longeveron's ELPIS II, Alumis in lupus, Kyverna in myasthenia gravis, Kodiak's DAYBREAK, Definium's second anxiety Phase 3, a PDUFA date on the 28th and an ASTRO poster on the 29th. There is no way to be positioned for all of it, which is the point of ranking them.

The backdrop is friendlier than it has been in two years. XBI has spent six months in one of its better stretches on record and sits in the mid-$160s, and roughly $106 billion of biotech M&A has printed across 201 transactions so far this year. Cheap capital and an open acquisition window change the shape of a bad readout — a failed trial in 2024 meant a death spiral, whereas in 2026 it more often means a strategic process. That is worth remembering when you read the Risk sections below.

The sharpest divide in this week's list is not scientific, it is financial. Seven of these companies are funded into 2028 or beyond and can afford to be wrong once. Six have a runway that ends at, or slightly after, the event itself — Karyopharm's liquidity guidance runs to September, and there is a $15.8 million principal payment due on the 10th. Same catalyst calendar, completely different consequence.

Housekeeping, and this one matters: this is the final weekly edition of the Scanner for now. I am taking the whole system apart — the data feeds, the scoring, the ranking — and rebuilding the parts that have been producing output I would not want to trade off myself. When it comes back it should be meaningfully more reliable. Deep-dive pieces continue in the meantime. Thank you for reading this thing every week; it will return in better shape.

What We're Tracking:

Regulatory Decisions and Filings Inside 90 Days: KPTI (sNDA, August), QURE (BLA, Q3), BFRI (PDUFA, Sep 28), ALMS (NDA, Q4), CADL (BLA, Q4), KYTX (rolling BLA completion, Q4), CLNN (NDA, early Q4)
Funded Well Past the Catalyst: QURE (into 2030), DFTX (into 2030), SCYX (into 2029), TYRA (into 2H 2028), KYTX (into 2028), GPCR (into 2028), CADL (into Q1 2028)
Runway Ends At or Near the Readout: KPTI (into September), LGVN (into Q4 2026), CLNN (through late Q4 2026), DWTX (through the Q4 readout), NTHI ($2.0M plus an undrawn credit line), BFRI ($4.7M, near operating breakeven)
Going-Concern Language on File: KPTI, GUTS, BOLT
Trading Below Net Cash: BOLT ($7.1M cap against $18.1M cash)
Overbought Into the Print (RSI > 75): IMMX (87), DWTX (85), IVVD (82), BFRI (82), CADL (75)
Deeply Oversold (RSI < 35): TYRA (29), CLNN (30)
Multi-Catalyst Within 90 Days: IVVD, QURE, SCYX, GPCR

FEATURED

#1. IMMX — Immix Biopharma, Inc.

THE CATALYST
Event: NXC-201 (NEXICART-2) — Phase 2 registrational topline in relapsed/refractory AL amyloidosis
Date: Q3 2026 (Est.)
FDA Status: BTD, ODD, RMAT
BSI: 7.87/10

Immix spent the first half of 2026 buying itself the right to stop worrying about money. A May underwritten offering raised $140.7 million net, an at-the-market facility added $13.9 million more in the second quarter, and the company now holds more cash than it has ever raised in total. It develops tissue-targeted cell therapies in oncology and immune-dysregulated disease, with no partner on the lead asset — so the balance sheet is the only thing standing between the data and a BLA.

📈 The Setup: AL amyloidosis is a plasma-cell disease in which misfolded antibody fragments deposit in the heart and kidneys, and the treatment bar is set by daratumumab (an anti-CD38 antibody) combinations that work well up front and leave heavily pretreated patients with almost nothing. NXC-201 is a BCMA-directed CAR-T — the patient's own T cells re-engineered to hunt the surface protein that marks the offending plasma cells. In the first 20 evaluable NEXICART-2 patients, all with a median of four prior lines, 19 achieved a complete response. Median time to initial response was seven days. No patient reaching CR has relapsed. Enrollment in the 40-patient BLA-enabling study is now complete, and the Q3 readout is the full dataset that goes into the filing — not another interim. RSI 87 tells you the market has already worked this out; the question is whether the back half of the enrollment looks like the front half.

✅ The Edge: No other BCMA CAR-T is running a registrational study in AL amyloidosis, and none has reported anything close to a 95% complete response rate in fourth-line patients. Breakthrough, Orphan and RMAT designations are all in hand, which is the regulatory package a single-arm BLA needs.
⚠️ The Risk: Twenty patients is twenty patients. The response rate has to hold through a doubled sample size, and CAR-T durability in a disease driven by organ damage is a longer question than a one-year follow-up answers. Manufacturing an autologous product at commercial scale has broken timelines for better-funded companies.

#2. QURE — uniQure N.V.

THE CATALYST
Event: AMT-130 — four-year Phase 1/2 topline and accelerated-approval BLA submission in Huntington's disease
Date: Q3 2026 (Est.)
Additional catalysts: 1 more within 90 days
BSI: 7.83/10

The FDA changed its mind, and uniQure immediately monetised it. A January Type A meeting ended without agreement on whether the Phase 1/2 dataset could support a filing at all; a June Type B meeting reversed that, accepting the three-year analysis as the primary basis for an accelerated-approval BLA and dropping the sham-surgery control demand. A $259 million follow-on followed within weeks. The company is Netherlands-domiciled and trades here as ADSs; it also collects royalties on an approved hemophilia B gene therapy licensed to CSL Behring.

📈 The Setup: Huntington's has no disease-modifying therapy — tetrabenazine and deutetrabenazine treat the chorea and nothing else — and every attempt to lower huntingtin protein before this one has either failed or stalled. AMT-130 is an AAV5 vector delivering an artificial microRNA (a small engineered RNA that silences a specific gene) directly into the striatum by intracranial infusion, so a single surgery is meant to permanently reduce mutant huntingtin production. At three years, high-dose patients showed 75% slowing of progression on the composite UHDRS scale against propensity-matched Enroll-HD controls (−0.38 versus −1.52, p=0.003), 60% slowing on Total Functional Capacity, and neurofilament light in spinal fluid 8.2% below baseline. September brings the four-year update and the filing together. Wave's WVE-003 and PTC518 are both years behind.

✅ The Edge: This is the only Huntington's program with an FDA-accepted regulatory path and the balance sheet to run the confirmatory trial without a partner. Four years of durability on an intracranially delivered one-time therapy is evidence no competitor can produce before 2029.
⚠️ The Risk: Twelve evaluable high-dose patients and an external control arm is a thin foundation, and the FDA still wants alignment on confirmatory study design before the submission goes in. Any four-year attenuation of the treatment effect — or a delayed surgical safety signal — reopens a question the June meeting had closed.

#3. IVVD — Invivyd, Inc.

THE CATALYST
Event: VYD2311 (DECLARATION and LIBERTY) — Phase 3 topline in COVID-19 prevention
Date: Q3 2026 (Est.)
FDA Status: FTD
Additional catalysts: 1 more within 90 days
BSI: 7.78/10

Invivyd is replacing its only commercial product on a clock the FDA set. PEMGARDA, its marketed antibody for pre-exposure prophylaxis in immunocompromised patients, is under a termination notice for its Emergency Use Authorization effective June 2027, even as it generated $14.3 million in the second quarter, up 21% year over year. The company works exclusively in antibody prophylaxis against evolving viral threats, has no partner on the next-generation molecule, and confirmed on August 13 that both pivotal trials had finished enrolling with topline analysis imminent. The stock is up more than 60% in three weeks.

📈 The Setup: Two Phase 3s read out at once and they ask different questions. VYD2311 is a monoclonal antibody — a pre-made infusion of protective protein that works on arrival and then wanes, as opposed to a vaccine that teaches the body to make its own. DECLARATION is the filing-enabling trial: roughly 1,770 participants, placebo-controlled, measuring reduction in PCR-confirmed symptomatic COVID at three months after a single intramuscular dose. LIBERTY is the commercial argument: a head-to-head safety and tolerability comparison against an mRNA vaccine, aimed squarely at the reactogenicity and myocarditis questions that have followed that class. Pfizer and Moderna own the pharmacy shelf and the seasonal habit; an antibody has to be visibly better tolerated to take space beside them. At a dollar a share the market is pricing one of these two trials working, not both.

✅ The Edge: No other monoclonal antibody is running a late-stage prevention study in a broad healthy population, and LIBERTY would give Invivyd the only randomised head-to-head tolerability dataset against an mRNA vaccine in existence — an asset worth more in the current policy environment than the trial design implies.
⚠️ The Risk: Placebo-controlled efficacy in COVID depends entirely on how many people in the control arm actually get sick. A quiet variant season produces an underpowered, inconclusive DECLARATION rather than a clean failure, and inconclusive is the worst possible result for a company whose revenue product expires by regulatory decree in ten months.

#4. KPTI — Karyopharm Therapeutics Inc.

THE CATALYST
Event: Selinexor + ruxolitinib (SENTRY) — sNDA submission under accelerated approval in JAK-inhibitor-naïve myelofibrosis, with Priority Review requested
Date: Aug 2026 (Est.)
FDA Status: FTD
BSI: 7.62/10

The drug and the capital structure are on separate clocks, and the capital structure is faster. Karyopharm sells XPOVIO commercially in multiple myeloma, missed its Phase 3 endometrial cancer primary endpoint in July, and has engaged Centerview to run a financing and strategic-alternatives process. Second-quarter liquidity of $65.4 million funds operations into September. A $15.8 million senior term-loan principal payment is due September 10, alongside a $10.0 million minimum liquidity covenant the company has said it may breach without further action.

📈 The Setup: Myelofibrosis scars the bone marrow and swells the spleen, and Incyte's ruxolitinib (Jakafi) has owned the front line for over a decade, with fedratinib, pacritinib and momelotinib carved into narrower cytopenic and relapsed niches. No combination regimen has ever been approved in the JAK-naïve setting. Selinexor comes at it sideways: it blocks XPO1, the nuclear export protein tumour cells use to pump tumour-suppressor proteins out of the nucleus where they would otherwise do their job. In the 353-patient Phase 3 SENTRY trial, adding selinexor to ruxolitinib produced SVR35 — a 35%-or-greater reduction in spleen volume at week 24 — in 50% of patients versus 28% on ruxolitinib alone, one-sided p<0.0001, with an immature survival trend favouring the combination. The symptom-score co-primary was missed. The FDA has already confirmed in writing that SVR35 qualifies as a reasonably likely surrogate endpoint here, which is why a filing is possible at all this month.

✅ The Edge: Written FDA agreement on the surrogate endpoint is the hard part of an accelerated-approval package, and Karyopharm has it. Near-doubling of spleen response in a blinded trial with no crossover would make selinexor the first combination ever approved in front-line myelofibrosis — and ruxolitinib's own label was built on the same endpoint.
⚠️ The Risk: The missed symptom co-primary hands reviewers a specific objection, and an accelerated approval typically arrives attached to a confirmatory-trial obligation this balance sheet cannot fund. With negative stockholders' equity and a principal payment due September 10, the company has no capacity to absorb even a three-month review delay.

#5. LGVN — Longeveron, Inc.

THE CATALYST
Event: Laromestrocel (ELPIS II) — Phase 2b topline in hypoplastic left heart syndrome
Date: Q3 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.49/10

Longeveron is reading out a trial the FDA no longer treats as pivotal. Following a 2026 Type C meeting, the agency rejected right-ventricular ejection fraction as an efficacy endpoint and removed ELPIS II's pivotal designation; because an NIH-mandated interim analysis had already occurred, no replacement primary endpoint can be agreed while the study runs. The FDA has said only highly objective outcomes — all-cause mortality, transplant-free survival, cardiac transplant, well-defined major adverse cardiac events — will be decisive. The Miami company develops allogeneic cell therapies and is now openly seeking partners to carry laromestrocel forward across indications.

📈 The Setup: Hypoplastic left heart syndrome is a birth defect in which the left side of the heart never forms properly, and there is no drug for it — the standard of care is a three-stage surgical reconstruction with substantial mortality between stages. Laromestrocel is an allogeneic mesenchymal stem cell product, made from a healthy donor's bone marrow rather than the patient's own, injected into the heart muscle during the second-stage operation. ELPIS I, a small Phase 1, reported 100% transplant-free survival to age five. ELPIS II is the only randomised controlled cell-therapy trial in the indication, it is fully enrolled, the independent monitoring committee has reviewed it without objection, and database lock is late August. Mesoblast's rexlemestrocel-L sits behind it. But the readout will be judged on a composite of hard outcomes the company assembled after the fact, submitted to an agency that has not agreed to it.

✅ The Edge: A survival or transplant-free-survival signal in an ultra-orphan paediatric condition with no pharmacological option is the one result that could force the FDA back to the table regardless of endpoint history — and the trial is randomised and controlled, which nothing else in this space is.
⚠️ The Risk: There is no pre-agreed primary endpoint. Even a directionally positive composite can be dismissed as post-hoc, and with $10.1 million funding operations only into the fourth quarter, the company reaches that conversation with no ability to run the confirmatory work an FDA "no" would require.

#6. KYTX — Kyverna Therapeutics, Inc.

THE CATALYST
Event: Miv-cel (KYSA-6) — extended Phase 2 follow-up topline in generalized myasthenia gravis
Date: Q3 2026 (Est.)
FDA Status: FTD, ODD, RMAT
BSI: 7.28/10

Three things arrive at Kyverna this quarter and only one of them is on the screen. Alongside the myasthenia gravis follow-up, twelve-month KYSA-8 data in stiff person syndrome reads out, and the rolling BLA in that indication completes in the fourth quarter. The FDA also granted RMAT designation in non-active secondary progressive multiple sclerosis this summer. The Emeryville company builds CD19-directed CAR-T therapies for neurologic autoimmune disease and manufactures miv-cel through a supply agreement with ElevateBio.

📈 The Setup: Generalized myasthenia gravis is treated as a chronic subscription — C5 inhibitors like eculizumab and ravulizumab, or FcRn blockers like nipocalimab, dosed indefinitely to suppress the antibodies attacking the neuromuscular junction. Miv-cel proposes a reset instead: a single infusion of the patient's own T cells, re-engineered to recognise CD19 and wipe out the B-cell population that manufactures those antibodies, after which the immune system repopulates. In the KYSA-6 Phase 2 portion, seven patients with moderate-to-severe disease received one dose and showed mean MG-ADL and QMG improvements of 8.5 and 11.3 points at 24 weeks, with responses visible by week two, durability out to 52 weeks in available follow-up, and most patients coming off their background immunosuppressants entirely. No grade 3 or worse cytokine release or neurotoxicity. Cartesian's Descartes-08 and Cabaletta's CABA-201 are the pipeline rivals; neither has this depth of follow-up.

✅ The Edge: The Phase 2 effect sizes already exceed the co-primary endpoints powering the ongoing Phase 3, which is an unusual position to be in before a confirmatory trial finishes enrolling. And the stiff person syndrome BLA means Kyverna could hold the first approved CAR-T in any autoimmune disease before the myasthenia data matures.
⚠️ The Risk: Seven patients. The magnitude of benefit at that sample size is as likely to reflect selection as biology, and the Phase 3 does not finish enrolling until mid-2027. No CAR-T has ever cleared a BLA in autoimmune disease, so the manufacturing and comparability requirements are genuinely untested.

#7. ALMS — Alumis Inc.

THE CATALYST
Event: Envudeucitinib (LUMUS) — potentially pivotal Phase 2b topline in systemic lupus erythematosus
Date: Q3 2026 (Est.)
BSI: 7.23/10

The psoriasis franchise is already won; this readout is about whether the drug is bigger than that. Envudeucitinib cleared both ONWARD Phase 3 trials in moderate-to-severe plaque psoriasis with superiority over placebo and apremilast, and the NDA goes in during the fourth quarter. Alumis absorbed ACELYRIN in a 2025 all-stock merger and has since deprioritised the acquired lonigutamab program. Second-quarter R&D fell to $85.3 million as the psoriasis trials wound down.

📈 The Setup: Lupus is where oral drugs go to fail. Placebo response rates run high, patient populations are heterogeneous, background steroids muddy every signal, and the market is held by injectable biologics and decades-old antimalarials. Envudeucitinib is an oral TYK2 inhibitor — TYK2 is the signalling enzyme that carries interferon and interleukin messages into immune cells, and this molecule is engineered for full 24-hour blockade rather than the partial coverage of BMS's approved deucravacitinib. That matters specifically in lupus, which is an interferon-driven disease. LUMUS is a 408-patient global trial reading BICLA response at week 48, built with stringent entry criteria, real-time endpoint adjudication, restricted concomitant medication and a mandated steroid taper — every one of those a direct response to how previous lupus trials fell apart. RSI 41 and a negative three-week trend suggest nobody is paying for this outcome yet.

✅ The Edge: Deucravacitinib has never been taken into a registrational lupus program, which leaves envudeucitinib as the most advanced oral candidate in a disease whose central biology — type I interferon signalling — runs directly through the target it blocks. Phase 3 psoriasis data already established the safety database.
⚠️ The Risk: Trial-design discipline reduces placebo noise but cannot manufacture efficacy, and BICLA has defeated better-validated mechanisms than this one. A miss also carries a second cost: it would define the molecule as a dermatology asset at a $3.1 billion valuation that clearly assumes more.

#8. SCYX — SCYNEXIS, Inc.

THE CATALYST
Event: SCY-247 — Phase 1 IV formulation topline in invasive candidiasis
Date: Q3 2026 (Est.)
Additional catalysts: 1 more within 90 days
BSI: 7.20/10

Quietly, this stopped being a pure antifungal company. The April acquisition of PXL-770 — now SCY-770, a direct AMPK activator with Orphan Drug designation in autosomal dominant polycystic kidney disease — reoriented SCYNEXIS toward rare disease, funded by a $40 million private placement that closed the same week and pushed the runway to 2029. A one-for-eight reverse split left roughly 10 million shares outstanding. First-generation ibrexafungerp remains licensed globally to GSK, which means the legacy asset generates royalties rather than costs.

📈 The Setup: Two Phase 1 readouts land in the same quarter on two unrelated diseases, which is unusual for a company this size. SCY-247 is a second-generation fungerp — a triterpenoid that inhibits glucan synthase, the enzyme fungi use to build their cell walls — and it kills Candida rather than merely stopping its growth, including the drug-resistant C. auris and echinocandin-resistant C. glabrata strains that hospitals increasingly cannot treat. Echinocandins such as caspofungin and micafungin define first-line therapy and are losing ground to exactly those organisms. The completed Phase 1 tested the intravenous formulation, which is the one that matters for hospitalised patients. SCY-770 reads out separately: a food-effect and pharmacokinetic study to pick the dose for a Phase 2 proof-of-concept in ADPKD starting in the fourth quarter. Two shots, one balance sheet, ten million shares.

✅ The Edge: Prior oral data showed SCY-247 hitting target exposures at materially lower doses than ibrexafungerp — the same class, better potency — and an IV plus oral pair would let a hospital start therapy intravenously and step down without switching drug class, which echinocandins cannot do.
⚠️ The Risk: These are Phase 1 studies in healthy volunteers and neither produces efficacy data. Antifungal development is littered with agents that bridged cleanly and then could not beat echinocandins on non-inferiority, and a tiny float amplifies the reaction to a bridging study that reads merely acceptable.

#9. CADL — Candel Therapeutics, Inc.

THE CATALYST
Event: Aglatimagene besadenovec (CAN-2409) — ASTRO 2026 poster presentation of quantitative digital pathology from the Phase 3 in localized prostate cancer
Date: Sep 29, 2026
FDA Status: FTD, RMAT
BSI: 7.10/10

Candel is behaving like a company that expects to sell something. A February follow-on raised $100 million net, roughly $30 million more came through the at-the-market facility, RTW Investments committed a further $100 million in royalty-based funding payable on FDA approval, and a Chief Commercial Officer arrived in June. The Needham company builds viral immunotherapies for solid tumours, and the BLA in prostate cancer is a fourth-quarter event.

📈 The Setup: Nothing has been added to curative-intent radiotherapy for localized prostate cancer in more than twenty years — the regimen is radiation with or without short-term androgen deprivation, full stop. CAN-2409 injects an adenovirus carrying the herpes thymidine kinase gene straight into the tumour; a subsequent course of valacyclovir is then converted inside those cells into a toxin, killing them in a manner that spills tumour antigens into view of the immune system. In the 745-patient Phase 3, disease-free survival improved 30% (HR 0.70, p=0.016) at a median 50.3 months, prostate-cancer-specific DFS improved 39% at 58 months, and two-year biopsies showed pathological complete response in 80% of treated patients versus 63% of controls. Read the September event precisely: the ASTRO poster is an AI-enabled digital pathology analysis of paired biopsies taken at baseline and two years after radiation, examining immune-cell infiltration in the tumour microenvironment. It is mechanistic supporting work. The efficacy result already happened.

✅ The Edge: A first-in-class addition to radiotherapy with a positive randomised Phase 3, RMAT and Fast Track designations, and $100 million of contracted royalty funding that releases on approval — an unusually complete package for a billion-dollar company that has not yet filed.
⚠️ The Risk: Disease-free survival is a surrogate, overall survival is immature, and the FDA can reasonably ask what a DFS gain means for men who would mostly have survived either way. More immediately: RSI 75 into a conference poster that contains no new efficacy data is the wrong risk to be holding, because the actual catalyst is the fourth-quarter filing.

#10. GUTS — Fractyl Health, Inc.

THE CATALYST
Event: Revita (REMAIN-1) — Midpoint Cohort one-year randomized and open-label extension data in post-GLP-1 weight maintenance
Date: Q3 2026 (Est.)
BSI: 6.89/10

The pivotal readout is the one that decides this company, and it is not this one. Fractyl reported one-year randomized Midpoint Cohort data in July; what arrives now is the extension. Six-month topline from the fully enrolled Pivotal Cohort follows in early Q4, with a De Novo marketing submission targeted for late in the same quarter. The Burlington company develops procedural and gene-therapy approaches to metabolic disease, and its second-quarter filing carries a going-concern qualification against runway guidance that reaches early 2027.

📈 The Setup: More than half the weight lost on a GLP-1 comes back once patients stop taking it, and the only durable alternative is bariatric surgery. Revita is a one-time endoscopic procedure — duodenal mucosal resurfacing, a controlled hydrothermal ablation of the intestinal lining intended to reset the nutrient-sensing signals that go wrong in metabolic disease — done in an outpatient session with no implant left behind. In the randomized, sham-controlled Midpoint Cohort, patients receiving a complete ablation of more than 14 centimetres retained up to 84% of their GLP-1-induced weight loss at one year against 46% for sham, with mean regain of 4.1% of body weight versus 13.5%. No device- or procedure-related serious adverse events. The catch is in the sample: ten patients against eight. The Pivotal Cohort runs roughly 315.

✅ The Edge: This is the only randomised sham-controlled evidence that anything holds weight off after GLP-1 discontinuation, and the effect concentrated in patients who got a complete ablation — a dose-response relationship that argues the mechanism is real rather than incidental.
⚠️ The Risk: Ablation length varied across operators, and the headline result comes from the subgroup where the procedure was done most thoroughly. If the pivotal cohort's larger, less selected population dilutes that effect, the De Novo submission does not happen and a going-concern company faces a financing into a failed print.

WATCHLIST

#11. BEAM — Beam Therapeutics Inc. [Genetic Disease / Base Editing]

Price: $29.76 | Cap: $3.07B | Cash: $1.11B | RSI: 68 | Momentum: +18.6%
BEAM-302 — Phase 1/2 updated data, late-breaking oral presentation at the ERS Congress in alpha-1 antitrypsin deficiency (Sep 08, 2026)
RMAT
BSI: 6.88/10

The Intel: Base editing rewrites a single DNA letter without cutting the strand, and BEAM-302 uses it to correct the PiZ mutation in SERPINA1 so the liver produces functional alpha-1 antitrypsin instead of the misfolded version that damages both liver and lung. Standard care — weekly plasma-derived augmentation infusions — replaces the missing protein and does nothing for the liver. As of the February cutoff, 29 patients had been dosed across both trial parts with follow-up to 18 months and no serious adverse events through 75 mg. Barcelona is where the pivotal-development case gets made.

#12. NTHI — NeOnc Technologies Holdings, Inc. [CNS Oncology]

Price: $4.68 | Cap: $121M | Cash: $2.0M (Jun 30) plus an undrawn $10M related-party credit line | RSI: 61 | Momentum: +36.3%
NEO100 — Phase 2a topline reported August 12 in recurrent IDH1-mutant high-grade glioma
BSI: 6.84/10

The Intel: The data are already out and they were good. NEO100 — perillyl alcohol delivered intranasally, which routes the drug along the olfactory pathway and sidesteps the blood-brain barrier that defeats most systemic agents — hit its primary endpoint with six-month progression-free survival of 48.9% against a pre-specified 20% standard-of-care benchmark in 24 patients, and median overall survival of 26.1 months. Recurrent IDH-mutant high-grade glioma has essentially no effective therapy after temozolomide and radiation; vorasidenib addresses low-grade disease, not this population. The constraint is now financial, not scientific: $2.0 million of cash against roughly $12 million of half-year operating burn means the next event is a raise.

#13. DFTX — Definium Therapeutics, Inc. [Neuropsychiatry]

Price: $44.91 | Cap: $6.03B | Cash: ~$1.1B (Jun 30), funded into 2030 | RSI: 58 | Momentum: +4.0%
DT120 ODT (Panorama) — Phase 3 topline in generalized anxiety disorder (Q3 2026 Est.)
BSI: 6.83/10

The Intel: DT120 is lysergide in an orally disintegrating tablet — a 5-HT2A receptor agonist dosed once under supervision, with the formulation designed for reliable absorption without swallowing. The company has now hit three Phase 3s: Emerge in major depression in June, and Voyage in GAD on August 12, where 214 patients showed statistically significant HAM-A improvement at week 12 plus every key secondary. Panorama is the confirmatory replication, and an $805 million offering means the outcome does not threaten the company. Understand what you are buying at a $6 billion valuation: this is a second look at a result already delivered, and replication trials are where you learn whether the first one was the drug or the trial.

#14. DWTX — Dogwood Therapeutics, Inc. [Pain / Non-Opioid]

Price: $2.49 | Cap: $85M | Cash: $9.6M | RSI: 85 | Momentum: +66.0%
Halneuron — Phase 2b topline in chemotherapy-induced neuropathic pain (Fall 2026); KOL event Sep 01, 2026
BSI: 6.80/10

The Intel: Halneuron blocks voltage-gated sodium channels, the proteins nerves use to fire pain signals, quieting the damaged sensory neurons that make chemotherapy-induced neuropathy so hard to treat — and it does so without an opioid mechanism, in an indication where duloxetine is the only agent with guideline support and its effect is modest. Enrollment reached 217 patients, with 220-plus targeted for adequate power. Two problems: the topline is a fall event rather than a September one, and cash of $9.6 million covers the readout and not much past it. RSI 85 after a 66% three-week run means the good outcome is substantially priced, and the financing follows either result.

#15. TYRA — Tyra Biosciences, Inc. [Oncology / FGFR]

Price: $26.05 | Cap: $1.55B | Cash: $353.9M (Jun 30), funded into 2H 2028 | RSI: 29 | Momentum: -15.0%
TYRA-300 (SURF302) — Phase 2 initial three-month complete response data from both dose cohorts in FGFR3-altered non-muscle invasive bladder cancer (Aug 2026 Est.)
BSI: 6.75/10

The Intel: TYRA-300 is a selective FGFR3 inhibitor, built to spare FGFR1 and FGFR2 and thereby avoid the hyperphosphatemia and ocular toxicity that limit pan-FGFR agents like erdafitinib. That selectivity matters most in low-grade intermediate-risk bladder cancer, where the alternative is repeated cystoscopic resection and patients are otherwise well — nobody tolerates a harsh drug for this. Over 20 patients are enrolled and the endpoint is complete response at three months. RSI 29 into a first efficacy readout, on a balance sheet funded through 2028, is the most contrarian entry on this list.

#16. BFRI — Biofrontera Inc. [Dermatology / Commercial]

Price: $1.48 | Cap: $22M | Cash: $4.7M (Jun 30) | RSI: 82 | Momentum: +35.8%
Ameluz + RhodoLED — PDUFA decision in superficial basal cell carcinoma (Sep 28, 2026)
BSI: 6.65/10

The Intel: Ameluz is a topical gel that tumour cells convert into protoporphyrin IX, a light-sensitive molecule; the RhodoLED red lamp then activates it to generate reactive oxygen and destroy the lesion without cutting. Approved in actinic keratosis and already commercial, it would become the first and only photodynamic photosensitizer labelled for superficial basal cell carcinoma — competing against Mohs surgery and excision on cosmetic outcome. The financials read better than the cash line suggests: Q2 revenue $12.0 million, up 33%, gross margin 80%, net loss $0.6 million and adjusted EBITDA roughly breakeven. This is a label expansion at a $22 million market cap, not a binary science bet.

#17. CLNN — Clene Inc. [Neurology / ALS]

Price: $4.32 | Cap: $56M | Cash: $9.7M (Jun 30) plus a $7.0M registered direct offering | RSI: 30 | Momentum: -19.9%
CNM-Au8 — accelerated-approval NDA submission in amyotrophic lateral sclerosis (early Q4 2026)
BSI: 6.58/10

The Intel: CNM-Au8 is a suspension of catalytically active gold nanocrystals that improves mitochondrial energy production in motor neurons — a mechanism that is not consumed the way a conventional drug is metabolised. The filing rests on neurofilament light as a biomarker plus survival data from the HEALEY platform trial, RESCUE-ALS and an NIH expanded-access protocol, where the 30 mg regimen showed median survival of 951 days against 753 in comparators. The bar is set by riluzole and edaravone, both marginal, and by the memory of Relyvrio's withdrawal after a confirmatory failure. Note the timing has moved to early Q4, and $11.5 million of convertible debt now matures in August 2027 — runway reaches late Q4 2026 and no further.

#18. KOD — Kodiak Sciences Inc. [Ophthalmology]

Price: $38.33 | Cap: $2.41B | Cash: $125.9M (Jun 30), into 2027 | RSI: 46 | Momentum: -7.4%
Zenkuda (tarcocimab tedromer) and KSI-501 (DAYBREAK) — Phase 3 one-year topline versus aflibercept in treatment-naïve wet AMD (September 2026)
BSI: 6.52/10

The Intel: DAYBREAK tests two molecules at once against aflibercept: Zenkuda, an anti-VEGF built on Kodiak's biopolymer conjugate platform with roughly a 20-day ocular half-life — about three times the approved agents — and KSI-501, which blocks VEGF and IL-6 together to address the inflammatory component that pure anti-VEGF therapy leaves untouched. The competitive bar is high and moving: aflibercept 8 mg and faricimab have both already extended dosing intervals. What makes this the tightest setup in the watchlist is arithmetic — $125.9 million of cash against roughly $65 million of quarterly burn, with a December readout in PEAK behind this one. September has to go well.

#19. GPCR — Structure Therapeutics Inc. [Obesity / Oral GLP-1]

Price: $49.09 | Cap: $3.50B | Cash: $1.3B (Jun 30), into 2028 | RSI: 52 | Momentum: -0.1%
Aleniglipron (ACCESS OLE) — 72-week tolerability and open-label extension data in obesity (Q3 2026 Est.)
BSI: 6.46/10

The Intel: Aleniglipron is an oral small-molecule GLP-1 receptor agonist — a pill rather than an injection, and not a peptide, so it avoids the food-and-water dosing restrictions oral semaglutide carries. Phase 2b results published in Nature Medicine showed up to 16.2% weight loss with reductions continuing past 36 weeks. Be precise about the Q3 event: it is 72-week open-label extension data testing whether a 2.5 mg starting titration fixes the tolerability profile, not a new efficacy readout, and the Phase 3 ACCOMPLISH program is only now dosing. Lilly's orforglipron is the reference point and is well ahead. Cayman-incorporated, trading here as ADSs.

#20. BOLT — Bolt Biotherapeutics, Inc. [Oncology / Immune-Stimulating Conjugates]

Price: $3.67 | Cap: $7.1M | Cash: $18.1M (Jun 30), into 1Q 2027 | RSI: 42 | Momentum: -4.3%
BDC-4182 — initial Phase 1/2 clinical data in gastric and gastroesophageal junction cancer (Q3 2026 Est.)
BSI: 6.42/10

The Intel: A $7.1 million market cap against $18.1 million of cash, with a going-concern warning attached — the market has written this off entirely. BDC-4182 targets Claudin 18.2, the tight-junction protein that zolbetuximab validated as a gastric cancer target, but instead of a cytotoxic payload it delivers a TLR agonist that switches on myeloid cells locally, recruiting innate immunity at the tumour rather than throughout the body. Early immune-activation signals prompted a protocol change to step-up dosing, borrowed from T-cell engagers. Initial data land with the third-quarter results. A 1.9-million-share float means any result at all moves this violently in both directions.

The Strategist's Take

If you only take one thing from this final issue, take the funding split. Seven of these twenty companies are financed into 2028 or later, and for them September is a milestone. Six reach the readout with the tank showing empty, and for them September is a deadline. Karyopharm is the clearest version: the SENTRY data are real, the FDA has already agreed in writing that spleen volume reduction supports an accelerated-approval filing, and none of that helps with a $15.8 million principal payment due on the 10th and liquidity guidance that stops in the same month. Longeveron reads out into $10.1 million and no agreed endpoint. Dogwood has cash through its own topline and not past it. In every one of those cases the trial outcome and the equity outcome are only loosely connected, and traders who model the science without modelling the balance sheet get the direction right and the position wrong.

The cleanest setups here are the ones where the hard part is already finished. uniQure has three-year data the FDA has explicitly accepted as the basis for a BLA, $810 million in the bank and a filing going in this quarter — the September readout extends a result rather than creating one. Immix has a 95% complete response rate in a disease with no fourth-line option, $232 million raised into it, and a registrational dataset arriving on a trial that has finished enrolling. Both are expensive on the tape, and RSI 87 on Immix is a real warning about entry price rather than about the thesis. But they are the two names on this list where a good outcome is a filing rather than a hope.

Then there is the category worth being most careful about, because it looks like a catalyst and is not one. Candel's September 29 event is a digital pathology poster, not new efficacy data — the Phase 3 read out months ago and the BLA is the fourth-quarter event, which makes RSI 75 into a conference abstract an odd risk to carry. Definium's Panorama is a replication of a Phase 3 that already succeeded on August 12, into a $6 billion valuation. Structure's Q3 data is a tolerability extension, not the obesity readout the ticker implies. NeOnc's Phase 2a has already printed, and printed well — what is left there is a financing. Getting the event type right is most of the work in this business, and it is the single thing a screen is worst at.

That is where I will leave it. This is the last weekly edition for now, and the reason is honest: the pipeline behind these lists needs to be better than it is. Data feeds lag quarterly filings, catalyst dates resolve to month-end placeholders that read as precision, and the scoring rewards cheapness in ways that do not always survive contact with a capital structure. Those are fixable problems and I would rather fix them than paper over them weekly. Deep-dive pieces continue in the meantime, and when the Scanner comes back it should earn more of your trust than this version did. Thank you for reading.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings; prices reflect the August 21 close, and cash figures are drawn from second-quarter 2026 filings and subsequent company disclosures. Catalyst dates are estimates based on company guidance and subject to change — entries marked "(Est.)" resolve to a month-end placeholder and should be read as windows, not dates.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-08-23T21:04:58